B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

VOLTAGE-GATED

MOLECULAR TARGET

Voltage-gated inwardly rectifying potassium channel KCNH2 (human)

UniProt: Q1280910 compounds

VOLTAGE-GATED (Voltage-gated inwardly rectifying potassium channel KCNH2 (human)) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting VOLTAGE-GATED

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Sertraline1.102
2Astemizole Antihistamine drug now withdrawn from1.102
3Carvedilol1.102
4dofetilide1.102
5Flunarizine Flunarizine is1.102
6Perphenazine1.102
7Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent0.691
8Cefiderocol0.691
9Celecoxib0.691
10Quinidine0.691

About VOLTAGE-GATED as a Drug Target

VOLTAGE-GATED (Voltage-gated inwardly rectifying potassium channel KCNH2 (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented VOLTAGE-GATED interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

VOLTAGE-GATED inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.